Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
R&D Expense Growth
0.00%
Quarterly · Period ending:
CANF R&D Expense Growth
Latest reported0.00%period ending
Latest reported0.00%period ending
CANF Quarterly R&D Growth (QoQ) (0.00% → 0.00%)
Latest values, visible window
High-resolution chart · PNG
CANF r&d expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 0% | |
| -5.548% | |
| 0% | |
| 20.5999% | |
| 0% | |
| 5.6407% | |
| 0% | |
| -0.4506% | |
| 0% | |
| 13.8516% | |
| -2.4634% | |
| -4.2035% | |
| -34.2067% | |
| -16.0147% | |
| 20.5305% | |
| 40.2204% | |
| -20.2636% | |
| -41.277% | |
| 5.5121% | |
| 17.2318% | |
| 92.4021% | |
| -55.0069% | |
| 44.7276% | |
| -39.0496% | |
| -12.9409% | |
| -4.7727% | |
| 29.5812% | |
| 21.4144% | |
| 74.4283% | |
| -28.529% | |
| 42.3836% | |
| 7.0189% | |
| 0.9139% | |
| -21.5581% | |
| 57.3579% | |
| -17.884% | |
| 4.5814% | |
| -36.9087% | |
| 28.3395% | |
| 1.5292% | |
| 39.7152% | |
| -23.9308% | |
| 54.6548% | |
| -1.7705% | |
| 58.6092% | |
| -25.0221% | |
| -8.7406% | |
| -39.593% | |
| 30.316% | |
| -30.1904% | |
| 121.3641% | |
| -37.276% | |
| 15.9152% | |
| -16.7939% | |
| 65.7911% | |
| 10.266% | |
| -40.8649% | |
| 38.8295% | |
| 11.5272% | |
| -23.5669% | |
| -22.069% | |
| 68.7658% | |
| 8.3787% | |
| 0% |